CA3249922A1 - OPHTHALMIC TOPICAL CREAM COMPOSITIONS - Google Patents

OPHTHALMIC TOPICAL CREAM COMPOSITIONS

Info

Publication number
CA3249922A1
CA3249922A1 CA3249922A CA3249922A CA3249922A1 CA 3249922 A1 CA3249922 A1 CA 3249922A1 CA 3249922 A CA3249922 A CA 3249922A CA 3249922 A CA3249922 A CA 3249922A CA 3249922 A1 CA3249922 A1 CA 3249922A1
Authority
CA
Canada
Prior art keywords
therapeutic treatment
treatment composition
ophthalmic therapeutic
ophthalmic
api
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249922A
Other languages
English (en)
French (fr)
Inventor
James Jane-Guo Shiah
Xiaojun Michael Liu
Gabriella Szekely
Original Assignee
Glaukos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaukos Corp filed Critical Glaukos Corp
Publication of CA3249922A1 publication Critical patent/CA3249922A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3249922A 2022-04-21 2023-04-19 OPHTHALMIC TOPICAL CREAM COMPOSITIONS Pending CA3249922A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263363356P 2022-04-21 2022-04-21
US63/363,356 2022-04-21
PCT/US2023/065956 WO2023205695A1 (en) 2022-04-21 2023-04-19 Ophthalmic topical cream compositions

Publications (1)

Publication Number Publication Date
CA3249922A1 true CA3249922A1 (en) 2023-10-26

Family

ID=86558713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249922A Pending CA3249922A1 (en) 2022-04-21 2023-04-19 OPHTHALMIC TOPICAL CREAM COMPOSITIONS

Country Status (7)

Country Link
US (2) US12414938B2 (cg-RX-API-DMAC7.html)
EP (1) EP4511001A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513344A (cg-RX-API-DMAC7.html)
CN (1) CN119584954A (cg-RX-API-DMAC7.html)
AU (1) AU2023257375A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249922A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023205695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060434A1 (en) * 2024-09-16 2026-03-19 Iview Therapeutics, Inc. Novel eyelid delivery of ophthalmic composition containing muscarinic receptor modulators for prevention and treatment of ocular disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752008T3 (es) 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US20120195969A1 (en) 2010-09-29 2012-08-02 Aidan Research And Consulting, Llc Treatment of acne by conditioned media
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
BR112015031885A2 (pt) 2013-06-18 2017-07-25 Lubrizol Advanced Mat Inc dispersões estáveis coloidalmente com base em galactomananas modificadas
CN113559105B (zh) 2014-01-29 2026-06-23 维奥姆治疗有限公司 抗性痤疮的治疗
US20170266289A1 (en) * 2014-08-27 2017-09-21 Abbvie Inc. Topical formulation
US20170087199A1 (en) 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
CA3032695C (en) * 2016-08-19 2021-11-23 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
JP6946575B2 (ja) 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドAllergan,Incorporated 眼の状態の治療のためのピロカルピン塩酸塩の使用
DK3870170T3 (da) * 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
WO2020141482A1 (en) * 2019-01-04 2020-07-09 Glenmark Specialty S.A. Pharmaceutical compositions comprising mupirocin
NZ781774A (en) * 2019-03-08 2023-03-31 Taro Pharma Ind Stable topical compositions of fenoldopam
US20220071924A1 (en) * 2019-03-19 2022-03-10 Sol-Gel Technologies Ltd. Treatment of ocular diseases with ophthalmic tapinarof compositions
WO2024026365A1 (en) 2022-07-26 2024-02-01 Glaukos Corporation Ophthalmic topical cream formulations and uses thereof

Also Published As

Publication number Publication date
JP2025513344A (ja) 2025-04-24
WO2023205695A1 (en) 2023-10-26
US20230381145A1 (en) 2023-11-30
US20250387372A1 (en) 2025-12-25
EP4511001A1 (en) 2025-02-26
US12414938B2 (en) 2025-09-16
AU2023257375A1 (en) 2024-11-07
CN119584954A (zh) 2025-03-07

Similar Documents

Publication Publication Date Title
US20230372303A1 (en) Applications of zwitterions in ophthalmic topical cream compositions and preparations
KR101809713B1 (ko) 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템
JP5705552B2 (ja) 眼痛を処置または防止するためのケトロラックトロメタミン組成物
WO2004058273A1 (en) Use of rimexolone in the treatment of dry eye
TW201105363A (en) Eye drop for macular edema treatment
US20250387372A1 (en) Ophthalmic topical cream compositions and methods
US5929115A (en) Anti-inflammatory eye drop
EP0517160B1 (en) Extended-release ophthalmic preparations
WO2013043387A1 (en) Ophthalmic gel compositions
JP2017501184A (ja) 低減された眼圧で術後の炎症を治療するための方法
KR101723703B1 (ko) 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물
US5443833A (en) Pharmaceutical compositions
JP4263418B2 (ja) 熱ゲル化人工涙液
JP2025513344A5 (cg-RX-API-DMAC7.html)
JPS63502270A (ja) 散瞳作用を有する眼科用医薬組成物
JPWO2020138135A1 (ja) 眼科用組成物
USRE38628E1 (en) Pharmaceutical compositions
KR100261585B1 (ko) 항염증점안제
CN116270442A (zh) 一种用于矫正近距离视力的眼用制剂
US20170128481A9 (en) Ocular treatment with reduced intraocular pressure
Mali et al. IN SITU GEL-FORMING SYSTEMS
HK1178446B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
HK1201464B (en) Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives
HK1149212B (en) Ketorolac tromethamine compositions for treating or preventing ocular pain

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241021

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250113

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250113

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250410

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250410

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260415